Company Overview - Grifols, S.A. is a global healthcare company headquartered in Barcelona, specializing in plasma-derived therapies, diagnostics, and hospital supplies, with a strong presence in over 100 countries [2]. Business Units and Focus Areas - The company's main business units include Bioscience, Diagnostics, and Hospital, focusing on immunotherapy, transfusion medicine, and critical care, addressing treatments for bleeding disorders, immunodeficiencies, and neurological conditions [2]. Expansion Plans - In mid-2025, Grifols announced plans to build a new manufacturing site in Spain, aimed at doubling its plasma fractionation capacity in Europe, reflecting a strategic commitment to meet rising demand for plasma-based therapies [3]. Financial Performance - Grifols reported a 7% increase in revenue to EUR 3,677 million in H1 2025, supported by its Value Creation Plan [3]. Market Positioning - The new facility in Spain is expected to strengthen Grifols' supply chain resilience and enhance its competitive position in the growing plasma therapeutics market, aiming to improve market share while addressing critical clinical needs [4].